• 제목/요약/키워드: Plasminogen activator inhibitor-1

검색결과 77건 처리시간 0.022초

Soluble Expression and Purification of Human Tissue-type Plasminogen Activator Protease Domain

  • Lee, Hak-Joo;Im, Ha-Na
    • Bulletin of the Korean Chemical Society
    • /
    • 제31권9호
    • /
    • pp.2607-2612
    • /
    • 2010
  • Human tissue-type plasminogen activator (tPA) is a valuable thrombolytic agent used to successfully treat acute myocardial infarction, thromboembolic stroke, peripheral arterial occlusion, and venous thromboembolism. Recombinant tPA is accumulated as an inactive form in inclusion bodies of E. coli and is refolded in vitro, which is accompanied by extensive aggregation. In the present study, a tPA protease domain was expressed in an active soluble form in the cytosol of E. coli Rosetta-gami cells, which allowed disulfide bond formation and supplied the tRNA molecules required for six rarely used codons in E. coli. This strategy increased the amount of soluble protease domain protein and avoided the cumbersome refolding process. The purified protease domain not only degraded tPA substrate peptides but also formed a covalently bound complex with plasminogen activator inhibitor-1, as does full-length tPA. Soluble expression and purification of tPA domains may aid in functional analyses of this multi-domain protein, which has been implicated in many physiological and pathological processes.

40,50대 남녀별 체중, BMI와 관상동맥질환 위험인자 간의 상관 정도 비교 (Correlations between Weight, Body Mass Index(BMI) and Risk Factors of Coronary Artery Disease in Men and Women in their Forties and Fifties)

  • 김희승;정혜선;한경실
    • 대한간호학회지
    • /
    • 제28권1호
    • /
    • pp.184-192
    • /
    • 1998
  • This study was done to examine the correlations between weight, BMI and risk factors of coronary heart disease in men and women in their forties and fifties. The subjects were 412 adults. who had regular health examinations between January and December of 1996 at S-Hospital in Seoul. The data were analyzed using ANOVA, Scheffe test, and Pearson correlation coefficient. The results are as follows : 1. The men between 50 and 59 years of age had higher levels for BMI, weight, systolic blood pressure, diastolic blood pressure, total cholesterol. LDL-cholesterol, triglyceride, fasting blood sugar, plasminogen activator-1, and hemoglobin A,C than the group of women in their forties. Yet. HDL-cholesterol was lower than in the former group. 2. In the group of men in their forties, weight was significantly correlated to diastolic blood pressure(r=.22), LDL-cholesterol(r=.20), plasminogen activator-inhibitor-1(r=.35) HDL-cholesterol(r=-.19). Their BMI was significantly correlted to systolic blood pressure(r=.27), diastolic blood pressure (r=.33), total cholesterol(r=.23), LDL-cholesterol (r=.26), plasminogen activator-1(r=.36) and HDL-cholesterol(r=-.25). 3. As for the group of women in their forties weight was significantly correlated to systolic blood pressure(r=.20), diastolic blood pressure(r=.22), triglyceride(r=.32) , plasminogen activator inhibitor-1 (r=.30) and HDL-cholesterol(r= -.37). Their BMI was significantly correlated to diastolic blood pressure (r=.25) triglyceride(r=.47), plasminogen activator-1 (r=.35), fibrinogen(r=.27) and HDL-cholesterol(r=-.47). 4. In the group of men in their fifties. weight was significantly correlated to total cholesterol (r=32), LDL-cholesterol(r=.29). plasminogen activator inhibitor-1(r=.26). Their BMI was significantly correlated to systolic blood pressure(r=.24), diastolic blood pressure (r=.22), total cholesterol (r=.34), LDL-cholesterol (r=.32), and plasminogen activator-1(r=.25). 5. In the group of women in their fifties, weight was significantly correlated to diastolic blood pressure(r=.33), total cholesterol(r=.21), LDL-cholesterol(r=.20), plasminogen activator inhibitor-1 (r=.43) and HDL-cholesterol(r=-.21). Their BMI was significantly correlated to systolic blood pressure(r=.25), diastolic blood pressure(r=.40), total cholesterol(r=.24), LDL-cholesterol(r=.24), triglyceride(r=22), and HDL-cholesterol (r=-.30). The above findings indicate that the BMI was more predictive than weight as a risk factor for coronary artery disease for men and women in their forties and fifties.

  • PDF

Transcriptional Upregulation of Plasminogen Activator Inhibitor-1 in Rat Primary Astrocytes by a Proteasomal Inhibitor MG132

  • Cho, Kyu Suk;Kwon, Kyoung Ja;Jeon, Se Jin;Joo, So Hyun;Kim, Ki Chan;Cheong, Jae Hoon;Bahn, Geon Ho;Kim, Hahn Young;Han, Seol Heui;Shin, Chan Young;Yang, Sung-Il
    • Biomolecules & Therapeutics
    • /
    • 제21권2호
    • /
    • pp.107-113
    • /
    • 2013
  • Plasminogen activator inhibitor-1 (PAI-1) is a member of serine protease inhibitor family, which regulates the activity of tissue plasminogen activator (tPA). In CNS, tPA/PAI-1 activity is involved in the regulation of a variety of cellular processes such as neuronal development, synaptic plasticity and cell survival. To gain a more insights into the regulatory mechanism modulating tPA/PAI-1 activity in brain, we investigated the effects of proteasome inhibitors on tPA/PAI-1 expression and activity in rat primary astrocytes, the major cell type expressing both tPA and PAI-1. We found that submicromolar concentration of MG132, a cell permeable peptide-aldehyde inhibitor of ubiquitin proteasome pathway selectively upregulates PAI-1 expression. Upregulation of PAI-1 mRNA as well as increased PAI-1 promoter reporter activity suggested that MG132 transcriptionally increased PAI-1 expression. The induction of PAI-1 downregulated tPA activity in rat primary astrocytes. Another proteasome inhibitor lactacystin similarly increased the expression of PAI-1 in rat primary astrocytes. MG132 activated MAPK pathways as well as PI3K/Akt pathways. Inhibitors of these signaling pathways reduced MG132-mediated upregulation of PAI-1 in varying degrees and most prominent effects were observed with SB203580, a p38 MAPK pathway inhibitor. The regulation of tPA/PAI-1 activity by proteasome inhibitor in rat primary astrocytes may underlie the observed CNS effects of MG132 such as neuroprotection.

가와사키병 환아에서 plasminogen activator inhibitor-1 유전자 다형성에 관한 연구 (Polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene in Kawasaki disease)

  • 한미영
    • Clinical and Experimental Pediatrics
    • /
    • 제50권6호
    • /
    • pp.570-575
    • /
    • 2007
  • 목 적 : 가와사키병과 PAI-1의 유전자 다형성의 연관성에 대한 연구를 시행하여 가와사키병 발병의 유전적 배경을 알아보고자 하였다. 방 법 : 경희대학교 부속 병원, 가천의과대학 부속 길병원, 을지대학교 부속 노원 을지병원 소아과에 입원하여 가와사키병으로 진단되었던 환아 56명과 정상 대조군 206명을 대상으로 PAI-1 촉진자의 중합 효소 연쇄반응을 시행하고 분석하였다. 결 과 : 가와사키병 환자 군과 정상 대조 군을 비교하였을 때 PAI-1-675 4G/5G 유전자형과 PAI-1-844 G/A의 유전자형의 사이에서 유의한 차이가 없었다. 또한 일시적인 관상 동맥 합병증이 있는 환자 군과 합병증이 없는 환자 군간을 비교했을 때 PAI-1-675 유전형과 PAI-1-844 유전형간에 의미 있는 차이를 보이지 않았다. 결 론 : 가와사키병에서 PAI-1의 촉진자 부위의 -844 G/A와 -675 4G/5G의 유전자 다형성의 차이는 관찰되지 않았으며 PAI-1유전자 다형성이 가와사키병에 대한 감수성에 관여할 가능성이 희박함을 알 수 있었다.

골수기질세포에서 방사선 반응 유전자로서의 Plasminogen Activator Inhibitor-1 (Plasminogen Activator Inhibitor-1 as a Radiation-Responsive Gene in Bone Marrow Stromal Cells)

  • 송지연;권형주;박찬규;조덕연;이영희
    • 한국발생생물학회지:발생과생식
    • /
    • 제9권1호
    • /
    • pp.43-48
    • /
    • 2005
  • 조혈세포의 주요 서식지가 되는 골수기질세포는 줄기세포의 운영을 결정하는 다양한 인자들을 제공한다. 방사선 요법은 항암치료법으로 널리 활용되고 있으나, 조혈세포의 파괴로 인한 부작용이 심각한 문제로서 조혈세포에 의한 혈액 세포가 빠른 시간 내에 회복되는 것이 필수적이다. 본 연구에서는 방사선을 조사했을 때의 줄기세포 서식지를 구성하는 세포인 골수기질세포에서 발현되는 유전자를 탐색하여 그 기능과 조절 및 혈액 형성을 이해하는 기초를 마련하고자 하였다. 방법론적으로는 polymerase chain reaction(PCR) 및 agarose 전기영동 방법을 활용한 differential display를 활용하였으며, 결과로서 여러 후보 유전자가 선별되었으나, plasminogen activator inhibitor-1(PAI-1) 유전자만이 감마선에 의해 유도됨이 반복 확인되었다. PAI-1 유전자 유도의 의미는 향후에 더 연구해야 할 것이다.

  • PDF

Relationship between Plasminogen Activity and Plasminogen Inhibitor during the Culture of Porcine Oviduct Epithelial Cells

  • Ahn, Shin-Hye;Cheong, Hee-Tae;Yang, Boo-Keun;Kim, Dae-Young;Park, Choon-Keun
    • Reproductive and Developmental Biology
    • /
    • 제33권4호
    • /
    • pp.203-209
    • /
    • 2009
  • The present study was performed to identify changes of plasminogen activator (PA) and plasminogen activator inhibitor (PAI) in porcine oviduct epithelial cells (POECs) during the estrous cycle. POECs obtained from ovary in pre-ovulatory (Pre-Ov), early to mid-luteal stage (Early-mid L) and post-ovulatory stage (Post-Ov). For the examine of PA activity, $1{\times}10^5$ fresh cells of POECs were cultured in DMEM/Ham F-12 containing 10% FBS and 0.2% amphotericin under humidified atmosphere of 5% $CO_2$ in air and $38^{\circ}C$. The urokinase-type PA (uPA) was observed at 7 days of POECs culture. PA activity was measured with culture prolonged of 0, 3, 6, 12 and 24 h after culture of 7 days. The PA activity were high significantly (p<0.05) at 12 h of culture, but PA activity were decreased with culture periods increased. The PA activity in POECs of Post-Ov stage were higher significantly (p<0.05) than that of Early-mid L and Pre-Ov stage. When PAI-1 and PAI-2 were added during the POECs culture, the PA were observed significant low activity (p<0.05). The PA activity and protein expression were decreased by PA inhibitor. This results suggest that PAI-1 and PAI-2 have a suppressive action on change of PA activity during the estrous cycle of pigs. Specifically, this study using PA inhibitor was effect the PA activity and PAI expression in oviduct epithelial cells in pigs.

Ascofuranone에 의한 plasminogen activator inhibitor-1 발현저해 효과 (Inhibitory Effect of LPS-Induced Plasminogen Activator Inhibitor-1 by Ascofuranone in Rat Kidney Fibroblast Cells)

  • 장영채
    • 생명과학회지
    • /
    • 제19권10호
    • /
    • pp.1438-1443
    • /
    • 2009
  • 이 연구는 신장섬유아 세포를 이용하여 LPS에 의해 유도된 신장섬유화 표적유전자인 plasminogen activator inhibitor (PAI-1) 발현과 Ascofuranone (AF)에 의한 신장섬유화 저해효과를 연구하였다. 이 연구를 통해 LPS가 PAI-1의 발현을 농도 및 시간 의존적으로 증가시켜 LPS가 신장섬유화 유도물질임을 확인 할 수 있었다. 또한 LPS로 유도된 PAI-1 mRNA 및 단백질 발현 레벨이 AF에 의해 저해되었으며, 신장섬유화의 또 다른 대표유전자인 fibronectin의 단백질 발현도 AF에 의해 억제되어 AF가 신장섬유화를 저해하는 사실을 확인할 수 있었다. 그리고 AF에 대한 PAI-1 프로모터 활성을 조사하기 위하여 p800-PAI-1-luc을 신장섬유아 세포에 형질전환 시킨 결과, AF가 PAI-1의 전사 활성 조절을 통해 발현을 억제한다는 것을 확인하였다. ERK-1/2의 상위에 존재하는 MEK inhibitor를 처리하여 PAI-1의 발현을 확인한 결과에서도 AF를 처리한 경우와 동일하게 PAI-1 발현이 저해되어 LPS로 유도된 PAI-1의 발현이 ERK-1/2에 의해 조절됨을 알 수 있었다. 또한 LPS로 유도된 ERK-1/2의 인산화가 AF 농도의존적으로 저해된 결과는, AF가 ERK-1/2의 활성저해를 통하여 PAI-1 발현을 조절한다는 사실을 확인 할 수 있었다. 따라서 이러한 연구결과 AF가 신장섬유화를 저해하는 유력한 후보물질로서의 가능성을 제시하였다.

Hormonal Regulation of Leptin, Resistin, and Plasminogen Activator Inhibitor-1 Gene Expression in 3T3-L1 Adipocytes

  • Lee, Hyun-Jung;Kim, Yang-Ha
    • Preventive Nutrition and Food Science
    • /
    • 제9권4호
    • /
    • pp.336-341
    • /
    • 2004
  • Leptin, resisitn and PAI-1 (plasminogen activator inhibitor-1) are synthesized and secreted by rodent fat cells and recently postulated to be an important link to obesity. This study was conducted to characterize the hormonal regulation of leptin, resistin, and PAI-1 gene expression in the 3T3-L1 adipocytes. The cells were treated with 0.5 $\mu$M insulin, 1 $\mu$M dexamethasone (Dex), or 0.05 $\mu$M triiodothyronine (T3) for 72 hours. The mRNA levels of each peptide were measured by semi-quantitative RT-PCR. The mRNA level of the leptin-producing ob gene was significantly increased by insulin, Dex, and T3 by 3.2-, 3.1- and 2.7-fold, respectively, compared to the control (p < 0.05). The level of resistin mRNA was increased by insulin, Dex, and T3 by 2.7-, 2.5- and 2-fold, respectively, compared to the control (p < 0.05). Likewise, the level of PAI-1 mRNA was significantly increased by insulin, Dex, and T3 compared to the control (p < 0.05). Taken together, our results suggest that insulin, Dex, and T3 may regulate the gene expression of leptin, resistin, and PAI-1 in 3T3-L1 adipocytes.

Aldosterone Up-regulates Production of Plasminogen Activator Inhibitor-1 by Renal Mesangial Cells

  • Yuan, Jun;Jia, Ruhan;Bao, Yan
    • BMB Reports
    • /
    • 제40권2호
    • /
    • pp.180-188
    • /
    • 2007
  • In vivo studies have demonstrated that aldosterone is an independent contributor to glomerulosclerosis. In the present study, we have investigated whether aldosterone itself mediated glomerulosclerosis, as angiotensin II (Ang II) did, by inducing cultured renal mesangial cells to produce plasminogen activator inhibitor-1 (PAI-1), and whether these effects were mediated by aldosterone-induced increase in transforming growth factor $\beta_1$ (TGF-$\beta_1$) expression and cellular reactive oxygen species (ROS) activity. Quiescent rat mesangial cells were treated by aldosterone alone or by combination of aldosterone and spironolactone, Ang II, neutralizing antibody to TGF-$\beta_1$ or antioxidant Nacetylcysteme (NAC). This study indicate that aldosterone can increase PAI-1 mRNA and protein expression by cultured mesangial cells alone, which is independent of aldosterone-induced increases in TGF-$\beta_1$ expression and cellular ROS. The effects on PAI-1, TGF-$\beta_1$ and ROS generation were markedly attenuated by spironolactone, a mineralocorticoid receptor antagonist, which demonstrate that mineralocorticoid receptor (MR) may play a role in mediating these effects of aldosterone.

Inhibition of Plasminogen Activator Inhibitor-1 Expression in Smoke-Exposed Alveolar Type II Epithelial Cells Attenuates Epithelial-Mesenchymal Transition

  • Song, Jeong-Sup;Kang, Chun-Mi
    • Tuberculosis and Respiratory Diseases
    • /
    • 제70권6호
    • /
    • pp.462-473
    • /
    • 2011
  • Background: Smoking is a risk factor for idiopathic pulmonary fibrosis (IPF), but the mechanism of the association remains obscure. There is evidence demonstrating that plasminogen activator inhibitor-1 (PAI-1) is involved in the progression of pulmonary fibrosis. This study was to determine whether the administration of small interfering RNA (siRNA) targeting PAI-1 or PAI-1 inhibitor to the cigarette smoking extract (CSE)-exposed rat alveolar type II epithelial cells (ATII cells) limits the epithelial-mesenchymal transition (EMT). Methods: ATII cells were isolated from lung of SD-rat using percoll gradient method and cultured with 5% CSE. The EMT was determined from the ATII cells by measuring the real-time RT PCR and western blotting after the PAI-1 siRNA transfection to the cells and after administration of tiplaxtinin, an inhibitor of PAI-1. The effect of PAI-1 inhibitor was also evaluated in the bleomycin-induced rats. Results: PAI-1 was overexpressed in the smoking exposed ATII cells and was directly associated with EMT. The EMT from the ATII cells was suppressed by PAI-1 siRNA transfection or administration of tiplaxtinin. Signaling pathways for EMT by smoking extract were through the phosphorylation of SMAD2 and ERK1/2, and finally Snail expression. Tiplaxtinin also suppressed the pulmonary fibrosis and PAI-1 expression in the bleomycin-induced rats. Conclusion: Our data shows that CSE induces rat ATII cells to undergo EMT by PAI-1 via SMAD2-ERK1/2-Snail activation. This suppression of EMT by PAI-1 siRNA transfection or PAI-1 inhibitor in primary type II alveolar epithelial cells might be involved in the attenuation of bleomycin-induced pulmonary fibrosis in rats.